Switch theme
Sign up to access all valuation multiples
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.
2007
9
LTM Revenue $0.1M
LTM EBITDA -$10.2M
$8.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Immunovia has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of -$10.2M.
In the most recent fiscal year, Immunovia achieved revenue of $0.1M and an EBITDA of -$6.3M.
Immunovia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Immunovia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | $0.1M | XXX | XXX | XXX |
| Gross Margin | 71% | XXX | 100% | XXX | XXX | XXX |
| EBITDA | -$10.2M | XXX | -$6.3M | XXX | XXX | XXX |
| EBITDA Margin | -7025% | XXX | -6581% | XXX | XXX | XXX |
| EBIT | -$11.1M | XXX | -$11.3M | XXX | XXX | XXX |
| EBIT Margin | -7593% | XXX | -11766% | XXX | XXX | XXX |
| Net Profit | -$9.0M | XXX | -$7.9M | XXX | XXX | XXX |
| Net Margin | -6183% | XXX | -8221% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Immunovia's stock price is SEK 0 (or $0).
Immunovia has current market cap of SEK 117M (or $12.1M), and EV of SEK 79.7M (or $8.2M).
See Immunovia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8.2M | $12.1M | XXX | XXX | XXX | XXX | $-0.07 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Immunovia has market cap of $12.1M and EV of $8.2M.
Immunovia's trades at 85.6x EV/Revenue multiple, and -1.3x EV/EBITDA.
Equity research analysts estimate Immunovia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Immunovia has a P/E ratio of -1.3x.
See valuation multiples for Immunovia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.1M | XXX | $12.1M | XXX | XXX | XXX |
| EV (current) | $8.2M | XXX | $8.2M | XXX | XXX | XXX |
| EV/Revenue | 56.4x | XXX | 85.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.8x | XXX | -1.3x | XXX | XXX | XXX |
| EV/EBIT | -0.7x | XXX | -0.7x | XXX | XXX | XXX |
| EV/Gross Profit | 79.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.5x | XXX | XXX | XXX |
| EV/FCF | -0.8x | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialImmunovia's last 12 month revenue growth is 334%
Immunovia's revenue per employee in the last FY averaged $11K, while opex per employee averaged $1.3M for the same period.
Immunovia's rule of 40 is -10241% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Immunovia's rule of X is -6190% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Immunovia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 334% | XXX | 259% | XXX | XXX | XXX |
| EBITDA Margin | -7025% | XXX | -6581% | XXX | XXX | XXX |
| EBITDA Growth | -4% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -10241% | XXX | -6246% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -6190% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $11K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 11866% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Immunovia acquired XXX companies to date.
Last acquisition by Immunovia was XXXXXXXX, XXXXX XXXXX XXXXXX . Immunovia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Immunovia founded? | Immunovia was founded in 2007. |
| Where is Immunovia headquartered? | Immunovia is headquartered in Sweden. |
| How many employees does Immunovia have? | As of today, Immunovia has 9 employees. |
| Who is the CEO of Immunovia? | Immunovia's CEO is Mr. Jeff Borcherding. |
| Is Immunovia publicy listed? | Yes, Immunovia is a public company listed on STO. |
| What is the stock symbol of Immunovia? | Immunovia trades under IMMNOV ticker. |
| When did Immunovia go public? | Immunovia went public in 2015. |
| Who are competitors of Immunovia? | Similar companies to Immunovia include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Immunovia? | Immunovia's current market cap is $12.1M |
| What is the current revenue of Immunovia? | Immunovia's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Immunovia? | Immunovia revenue growth (NTM/LTM) is 334%. |
| What is the current EV/Revenue multiple of Immunovia? | Current revenue multiple of Immunovia is 56.4x. |
| Is Immunovia profitable? | Yes, Immunovia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Immunovia? | Immunovia's last 12 months EBITDA is -$10.2M. |
| What is Immunovia's EBITDA margin? | Immunovia's last 12 months EBITDA margin is -7025%. |
| What is the current EV/EBITDA multiple of Immunovia? | Current EBITDA multiple of Immunovia is -0.8x. |
| What is the current FCF of Immunovia? | Immunovia's last 12 months FCF is -$10.0M. |
| What is Immunovia's FCF margin? | Immunovia's last 12 months FCF margin is -6832%. |
| What is the current EV/FCF multiple of Immunovia? | Current FCF multiple of Immunovia is -0.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
